Table 2 Patient characteristics
From: Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
Patient characteristics | Total (%) |
|---|---|
No. of patients | 34 |
Male/female | 24/10 |
Age at diagnosis, mean (range) | 63 (23–86) |
% blasts at diagnosis (morphology), mean (range) | 41.5 (20–96) |
% blasts at diagnosis (flow), mean (range) | 42.5 (9–86) |
WBC count at diagnosis, 109/L, median (range) | 4.5 (0.71–179) |
De novo/secondary AML | 27 (79)/7 (21) |
FAB classification, n (%) | |
M0 | 0 (0) |
M1 | 8 (24) |
M2 | 10 (29) |
M3 | 1 (3) |
M4 | 2 (6) |
M5 | 4 (12) |
M6 | 1 (3) |
M7 | 0 (0) |
Not classified | 8 (24) |
Cytogenetic risk group, n (%) | |
Favorable | 2 (6) |
Intermediate | 19 (56) |
Poor | 12 (35) |
No metaphases | 1 (3) |
FLT3/ITD, n (%) | |
Present | 10 (29) |
Absent | 15 (44) |
Not analyzed | 9 (26) |
CD123, n (%) | |
Present | 32 (94 %) |
Absent | 2 (6 %) |